Pfizer
New York, New York, United States · Biopharma, Biotechnology, Health Care
Seagen is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates and has a portfolio of targeted therapies. Seagen is recognized for its advancements in cancer care and plays a significant role in the oncology market. Its dedication to research and development underpins its success in the competitive biotech land
Key facts
- Headquarters
- New York, New York, United States
- Employees
- 81,000
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (PFE)
- Website
- pfizer.com
- Company page
Recent activity at Pfizer
- : SEC 8-K (7.01): Pfizer has made a Regulation FD Disclosure regarding the transition of its Chief Financial Officer on June 18, 2026, while reaffirming its fiscal year 2026 guidance. The guidance includes anticipated revenues between $59.5 billion and $62.5 billion and an Adjusted Diluted EPS in the range of $2.80 to $3.00. This affirmation follows the initial guidance introduced on December 16, 2025, and reaffirmed during the first quarter earnings call on May 5, 2026. The recent leadership change and continued financial guidance are crucial for investors and may impact overall strategic direction and investor confidence.
- : SEC 8-K (5.02): On June 16, 2026, Dave Denton notified Pfizer Inc. of his decision to step down as Chief Financial Officer, effective August 15, 2026, due to a new professional opportunity outside the pharmaceutical industry. His departure is not related to any issues regarding the Company’s financial performance. To ensure continuity, Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, will assume the role of Interim Chief Financial Officer starting August 16, 2026, while Pfizer conducts a search for Mr. Denton's permanent successor. This transition is strategically significant for Pfizer as it approaches critical operational phases in their pharmaceutical offerings.
- : Pfizer and Innovent Biologics Form Global Collaboration to Develop Cancer Medicines
- : Pfizer completes $43 billion acquisition of Seagen
- : SEC 8-K (7.01): On December 16, 2025, Pfizer Inc. issued a press release providing its full-year 2026 guidance and revised its full-year 2025 revenue guidance. The company reaffirmed all other components of its full-year 2025 financial guidance. This press release is significant for investors as it outlines expectations for the company's financial performance in 2026 and adjustments for 2025, which may affect investor sentiment and stock performance. The press release is filed as Exhibit 99.1.
- : SEC 8-K (8.01): On November 21, 2025, Pfizer Inc. completed a public offering of various notes totaling $5.5 billion, including Floating Rate Notes due 2027, 3.875% Notes due 2027, and several other notes with varying rates and due dates, such as 4.500% Notes due 2032 and 5.700% Notes due 2065. This issuance was conducted under a shelf registration statement originally filed on February 23, 2024, allowing for streamlined offer procedures. The company entered into underwriting agreements dated November 18, 2025, with major financial institutions including Citigroup and J.P. Morgan, implicating potential benefits for liquidity and capital financing. This public offering aims to strengthen Pfizer's capital structure while enabling investments in growth-oriented initiatives.
- : SEC 8-K (8.01): On November 13, 2025, Pfizer Inc. completed the acquisition of Metsera, Inc. pursuant to the Merger Agreement dated September 21, 2025, with amendments on November 7, 2025. Each share of Metsera common stock was converted into $65.60 in cash, representing an enterprise value of approximately $7.0 billion. Additionally, shareholders of Metsera will receive contingent value rights for potential payments up to $20.65 per share tied to specific milestones including clinical trial initiation and FDA approvals. This acquisition enhances Pfizer's product portfolio significantly and positions it to capitalize on potential future therapies.
- : SEC 8-K (2.02): On November 4, 2025, Pfizer Inc. announced its financial results for the third quarter of 2025. This disclosure includes important financial metrics that provide insights into the company's operational performance and strategic direction. The results may impact investor perceptions and market performance as they reflect the company's position and any changes in revenue, profit margins, and business outlook. Further details can be found in the accompanying press release attached as Exhibit 99.
- : Pfizer secures clearance for Metsera acquisition
- : Pfizer acquires Metsera for $7.3 billion
Leadership
- Nico Gariboldi, Vice President - Thessaloniki Site Lead
- Albert Bourla, Chief Executive Officer
- Patrizia Cavazzoni, Chief Medical Officer
- Elif Aral, President
- Lidia Fonseca, Chief Digital And Technology Officer
- Berta Rodriguez-Hervas, Chief Ai and Analytics Officer
- Albert Bourla, Chairman
- Mikael Dolsten, Chief Scientific Officer
- Andrew Baum, M.D., Chief Strategy And Innovation Officer
- Andrew Baum, Vice President
- Chris Boshoff, Chief Oncology Officer
- John Crowley
Verified email and direct lines for Pfizer’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Pfizer files 87 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Nov 2026.
Pfizer in the news
- Looking Beyond Weight Loss: The Future of Obesity Care - Pfizer (Oct 29, 2026)
- Pfizer Atirmociclib Breast Cancer Research Grants 2027: $8 Million Funding Pool - Oncodaily (Oct 25, 2026)
- Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma - Business Wire (Oct 27, 2026)
- Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting - Business Wire (Oct 26, 2026)
- Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare - Pfizer (Aug 27, 2024)
- FDA Approves Talazoparib Plus Enzalutamide for HRR-Mutated mHSPC - The American Journal of Managed Care (Oct 26, 2026)
- EU prosecutors still have questions for von der Leyen over Pfizergate - POLITICO.eu (Oct 28, 2026)
- Three Principles of Responsibility for Artificial Intelligence (AI) in Healthcare - Pfizer (Feb 09, 2023)
Companies similar to Pfizer
- Santhera Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, pharmaceuticals, Therapeutics
- Minerva Neurosciences · Biopharma, Biotechnology, Health Care, Pharmaceutical, pharmaceuticals, Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Bristol Myers Squibb · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Longboard Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Pfizer: questions and answers
What does Pfizer do?
Seagen is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates and has a portfolio of targeted therapies. Seagen is recognized for its advancements in cancer care and plays a significant role in the oncology market. Its dedication to research and development underpins its success in the competitive biotech land
Where is Pfizer headquartered?
Pfizer is headquartered in New York, New York, United States.
How many employees does Pfizer have?
Pfizer has about 81,000 employees.
Who leads Pfizer?
Nico Gariboldi is a Vice President - Thessaloniki Site Lead at Pfizer.
What is the latest news on Pfizer?
On Jun 18, 2026, SEC 8-K (7.01): Pfizer has made a Regulation FD Disclosure regarding the transition of its Chief Financial Officer on June 18, 2026, while reaffirming its fiscal year 2026 guidance. The guidance includes anticipated revenues between $59.5 billion and $62.5 billion and an Adjusted Diluted EPS in the
Is Pfizer a public company?
Yes. Pfizer is publicly traded under the ticker PFE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy